A Phase 3 interventional study of MK0217, /Duration of Treatment : 12 Months and Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months in Osteoporosis, Postmenopausal, sponsored by Organon and Co. Completed. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 400 is above the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Organon and Co is the lead sponsor of 478 studies on the registry; none are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 17 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bone Mineral Density (BMD) in PA lumbar spine at 12 months
Bone Mineral Density (BMD) in hip at 12 months; bone turnover at 6 and 12 months
No study locations are listed for this record.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Organon and Co